These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 7742591)
41. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy? Stewart A Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683 [No Abstract] [Full Text] [Related]
42. Antisense therapy in the treatment of hypercholesterolemia. Lippi G; Favaloro EJ Eur J Intern Med; 2011 Dec; 22(6):541-6. PubMed ID: 22075277 [TBL] [Abstract][Full Text] [Related]
43. Antisense strategies for the treatment of hematological malignancies and solid tumors. Kronenwett R; Haas R Ann Hematol; 1998; 77(1-2):1-12. PubMed ID: 9760146 [TBL] [Abstract][Full Text] [Related]
44. Antisense oligonucleotides: a new therapeutic approach. Temsamani J; Guinot P Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101 [TBL] [Abstract][Full Text] [Related]
45. Antisense comes of age. Flanagan WM Cancer Metastasis Rev; 1998 Jun; 17(2):169-76. PubMed ID: 9770113 [TBL] [Abstract][Full Text] [Related]
46. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease. Green DW; Roh H; Pippin J; Drebin JA J Am Coll Surg; 2000 Jul; 191(1):93-105. PubMed ID: 10898188 [No Abstract] [Full Text] [Related]
47. An overview of progress in antisense therapeutics. Crooke ST Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):115-22. PubMed ID: 9593049 [No Abstract] [Full Text] [Related]
48. Preclinical and clinical pharmacology of antisense oligonucleotides. Marcusson EG; Yacyshyn BR; Shanahan WR; Dean NM Mol Biotechnol; 1999 Aug; 12(1):1-11. PubMed ID: 10554769 [TBL] [Abstract][Full Text] [Related]
53. Antisense therapy in clinical oncology: preclinical and clinical experiences. Tamm I; Wagner M Mol Biotechnol; 2006 Jul; 33(3):221-38. PubMed ID: 16946452 [TBL] [Abstract][Full Text] [Related]
54. Nucleic acid therapeutics: state of the art and future prospects. Gewirtz AM; Sokol DL; Ratajczak MZ Blood; 1998 Aug; 92(3):712-36. PubMed ID: 9680338 [No Abstract] [Full Text] [Related]
55. Antisense therapy for lymphomas. Cotter FE Hematol Oncol; 1997 Feb; 15(1):3-11. PubMed ID: 9378470 [TBL] [Abstract][Full Text] [Related]
56. Antisense therapeutics in oncology: points to consider in their clinical evaluation. Mani S; Gu Y; Wadler S; Fingert H Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):543-7. PubMed ID: 10645781 [TBL] [Abstract][Full Text] [Related]
57. Antisense regulation of oncogenes in human cancer. Mukhopadhyay T; Roth JA Crit Rev Oncog; 1996; 7(3-4):151-90. PubMed ID: 9258601 [TBL] [Abstract][Full Text] [Related]
58. In vivo antisense imaging. Tavitian B Q J Nucl Med; 2000 Sep; 44(3):236-55. PubMed ID: 11105588 [TBL] [Abstract][Full Text] [Related]
59. Genetic medicine--when will it come to the drugstore? Wittung-Stafshede P Science; 1998 Jul; 281(5377):657-8. PubMed ID: 9714674 [No Abstract] [Full Text] [Related]
60. Transcription factors: new targets for antiallergic therapy. Quarcoo D; Hamelmann E Pathobiology; 2002-2003; 70(5):293-6. PubMed ID: 12771512 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]